Key Takeaways
- The Tobacco (Control of Advertisements and Sale) (Amendment) and Other Matters Bill was introduced on Feb. 12
- The bill proposes renaming the law to the Tobacco and Vaporisers Control Act
- Proposed maximum penalties: users up to S$10,000; sellers up to S$200,000 and six years’ jail; smugglers up to S$300,000 and nine years’ jail
- Current maxima cited: users up to S$2,000; distributors/importers/sellers up to six months’ jail and S$10,000 fine (double for repeat offenders)
- The bill proposes listing etomidate and analogues as specified psychoactive substances, with a broader scope for treatment and rehabilitation measures
2Firsts, February 28, 2026
According to The Straits Times, Singapore’s government has proposed new anti-vape laws that would substantially increase maximum penalties for vaping-related offences.
The Tobacco (Control of Advertisements and Sale) (Amendment) and Other Matters Bill was introduced in Parliament on Feb. 12 and proposes significant changes to the current Tobacco (Control of Advertisements and Sale) Act, including renaming it the Tobacco and Vaporisers Control Act.
If passed, the bill would raise maximum penalties so that vape users could face fines of up to S$10,000 (about US$7,800 at S$1 = US$0.78). Sellers could be fined up to S$200,000 (about US$156,000) and jailed for up to six years, while smugglers could be fined up to S$300,000 (about US$234,000) and jailed for up to nine years.
The text also sets out the current maximum penalties: users face up to S$2,000 (about US$1,560), and anyone who distributes, imports or sells vapes and components can be jailed for up to six months and fined up to S$10,000 (about US$7,800), with maximum penalties doubled for repeat offenders.
The bill also proposes introducing a new definition of specified psychoactive substances and listing the anaesthetic agent etomidate and its analogues under that framework. The text states this would broaden the scope of the Act and provide for the treatment and rehabilitation of those who abuse such substances.
Etomidate has been listed under the Misuse of Drugs Act as a Class C drug since Sept. 1, 2025, amid an increase in etomidate-laced vapes known as Kpods. The text sets out existing penalties tied to that listing and notes that the temporary listing was extended to April 30, 2026 while amendments are drafted.
Image source: The Straits Times
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
